|
|
|
96-week data support. The Baraclude Effect Pages 2 and 3 of 3
|
Entecavir (INN) (pronounced /ɛnˈtɛkəvɪr/) is an oral antiviral drug used in the treatment of hepatitis B infection. It is marketed under the trade name Baraclude (BMS).
Entecavir is a guanine analogue that inhibits all three steps in the viral replication process, and the manufacturer claims that it is more efficacious than previous agents used to treat hepatitis B (lamivudine and adefovir). It was approved by the U.S. Food and Drug Administration (FDA) in March 2005.
|
|
| Rate this file (No vote yet) |
|
|
|
|
|
|
